

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/02105 A1

(51) International Patent Classification?: A61K 31/202, A61P 25/18 // (A61K 31/202, 31:202)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/GB01/02717

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0016045.7 29 June 2000 (29.06.2000) GB

(71) Applicant (for all designated States except US): LAXDALE LIMITED [GB/GB]; Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 8JQ (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): HORROBIN, David, Frederick [GB/GB]; Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 8JQ (GB).

(74) Agent: WAKERLEY, Helen, Rachael; Reddie & Grose, 16 Theobalds Road, London WC1X 8PL (GB).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC COMBINATIONS OF FATTY ACIDS

ESSENTIAL FATTY ACID (EFA) METABOLISM

	n-6 series	n-3 series	
18:2n-6	LINOLEIC ↓ Delta-6-desaturation	ALPHA LINOLENIC	18:3n-3
18:3n-6	GAMMA-LINOLENIC ↓ Elongation	STEARIDONIC	18:4n-3
20:3n-6	DIHOMOGAMMALINOLENIC ↓ Delta-5-desaturation	EICOSA TETRAENOIC (n-3)	20:4n-3
20:4n-6	ARACHIDONIC ↓ Elongation	EICOSAPENTAENOIC	20:5n-3
22:4n-6	ADRENIC ↓ Delta-4-desaturation	DOCOSAPENT AENOIC (n-3)	22:5n-3
22:5n-6	DOCOSAPENTAENOIC (n-6)	DOCOSAHEXAENOIC	22:6n-3

(57) Abstract: Eicosapentaenoic acid or any appropriate derivative (EPA) is disclosed in combination with arachidonic acid (AA) or an AA precursor, selected from DGLA and GLA, to give a pharmaceutical formulation.

WO 02/02105 A1

- 1 -

Therapeutic Combinations of Fatty Acids

There are two series of essential fatty acids (EFAs) in humans. They are termed "essential" because they cannot be synthesised de novo in mammals. Their metabolic pathways are shown in figure 1. These fatty acids can be interconverted within a series, but the omega-6 (n-6) series cannot be converted to the omega-3 series nor can the omega-3 (n-3) series be converted to the omega-6 series in humans. The main EFAs in the diet are linoleic acid of the omega-6 series and alpha-linolenic acid of the omega-3 series. However, to fulfil most of their biological effects these "parent" EFAs must be metabolised to the other fatty acids shown in figure 1. Each fatty acid probably has a specific role in the body.

Particularly important in the n-6 series are dihomogammalinolenic acid (DGLA, 20:3n-6) and arachidonic acid (AA, 20:4n-6), while particularly important in the n-3 series are eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (22:6n-3). This patent specification particularly concerns combinations of AA and EPA.

AA is found as an important constituent of all cell membranes and particularly of cell membranes of nerve cells. It is an important component of many signal transduction systems which are activated by many different forms of cell stimulation. AA is usually found in cells in the form of phospholipids. Cell activation generates a range of active phospholipases which can release AA as the free acid. The free acid has many direct actions of its own in regulating protein kinases and other enzymes, in modulating movements of calcium and other ions, in activating receptors such as peroxisome proliferator activated receptors (PPARs), and in modulating gene function. Furthermore AA can be converted to an enormous

- 2 -

range of even more active derivatives known by the general name of eicosanoids. These include prostaglandins, leukotrienes, thromboxanes, various types of hydroxy acids, lipoxins, hepxoxilins and many other compounds.

5 These substances are often involved in inflammatory and thrombotic reactions and are frequently regarded as harmful in their overall effects. This harmful image is illustrated by the fact that intravenous AA is frequently lethal because of its thrombotic effects, and by the fact

10 that the steroids which are widely used, in particular for their anti-inflammatory effects, block the release of AA by phospholipases. Moreover, the class of drugs known as cyclo-oxygenase inhibitors, which include aspirin and many other well known compounds, known for their antithrombotic

15 and anti-inflammatory effects, inhibit the conversion of AA to prostaglandins and thromboxanes.

This concept of the potential toxicity of AA has become well established. The expert organisation in the field, the International Society for the Study of Fatty Acids and Lipids (ISSFAL) in 1999 organised a workshop in association with the US National Institutes of Health. The remit of the workshop was to make recommendations concerning the human uses of EFAs. The participants, all leading experts in the field, had no doubts about the harmful effects of AA, and emphasised this in their final statement (AP Simopoulos et al, Essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids, Nutrition and Metabolism 1999; 43:127-130). The ISSFAL newsletter reporting on this workshop stated that

20 "after much discussion, consensus was reached on the importance of reducing the omega-6 polyunsaturated fatty acids (PUFAs) even as the omega-3 PUFAs are increased in the diet of adults and newborns for optimal brain and cardiovascular function. This is necessary to reduce

25

30

- 3 -

adverse effects of arachidonic acid and its eicosanoid products".

In contrast to this general view of AA toxicity, the experts of ISSFAL and NIH were keen to promote the value 5 of the n-3 EFAs, particularly EPA and DHA for human health. The view was taken that EPA and DHA would replace AA in cell membrane phospholipids and also reduce AA synthesis from linoleic acid. The lowering of AA levels by EPA and/or DHA was expected to have widespread 10 beneficial effects on human health.

The present invention results from recent surprising observations of the inventor which suggest that this view may be wrong. Contrary to the general expert opinion, it has now been found that AA is highly desirable rather than 15 undesirable and it may be helpful to administer AA in association with EPA. The present invention provides this combination treatment.

The present invention provides pharmaceutical 20 formulations containing eicosapentaenoic acid or any appropriate derivative (hereinafter collectively referred to as EPA) and arachidonic acid (AA), as set out in the claims attached hereto. AA may be replaced by one or more of its precursors, DGLA or GLA. The ratio of EPA to AA is preferably between 1:1 and 20:1.

25 The EPA is preferably provided in a dose of between 100 mg and 10,000mg/day. The formulation may be a single preparation comprising 100-10,000 mg EPA. An alternative upper limit is 5,000 mg EPA. Preferably, the formulations 30 of the invention comprise 1 - 4 g EPA and 0.1 - 2.0 g arachidonic acid (AA). Still preferred amounts are 1.5 - 3g EPA and 0.2 - 1g AA.

- 4 -

The formulation may be a single daily dose preparation to give in one dose the above intakes, or may be in convenient divided doses, for example, a daily dose formed of four soft gelatin or other capsules, each containing 5 500 mg of EPA in an appropriate form and 150mg of AA in an appropriate form.

10 The compositions of the first aspect of the present invention are prepared by combining EPA in biologically assimilable form in which the EPA is at least 50% pure, preferably at least 90% pure, and arachidonic acid (AA) in any biologically assimilable form. The starting materials must include one containing substantial amounts of the EPA. The same can apply for the AA, which may be at least 30% pure, preferably at least 90% pure.

15 Still preferably, the active ingredient of the formulations of the present invention consists essentially wholly of the EPA and AA or AA precursor. In that case, no significant amounts of other EFAs are present.

20 Flavourants or emulsifiers may be included to make the preparation palatable. Other conventional additives, diluents and excipients may be present. The preparation for ingestion may be in the form of a capsule, a dry powder, a tablet, an oil, an emulsion or any other appropriate form. The capsules may be hard or soft 25 gelatin capsules, agar capsules, or any other appropriate capsule.

30 The EPA is preferably composed of a triglyceride or ethyl ester which is 50% pure or purer, more preferably more than 90% pure. Other forms of the fatty acids which may be useful include the free acids, salts, esters of any type, amides, mono-, di- or triglycerides, phospholipids or any other form which can lead to the incorporation of

- 5 -

EPA into body tissues. If phospholipids are considered, it is specifically excluded from the present invention that a phospholipid containing two different fatty acids, that is containing both EPA and AA (or AA precursor) is used. Phospholipids containing EPA may however be used in the present formulations when combined with phospholipids containing AA or AA precursor.

The formulations of the present invention may be used for the treatment of a wide range of diseases and disorders including:

any psychiatric, neurological or other central or peripheral nervous system disease - in particular schizophrenia, depression, bipolar disorder and degenerative disorders of the brain including Alzheimer's disease and other dementias and Parkinson's disease;

asthma and other respiratory diseases;

diseases of the gastrointestinal tract including inflammatory bowel diseases and irritable bowel syndrome;

inflammatory disease affecting any system;

cardiovascular disease;

dyslipidaemia, any form of diabetes or any form of metabolic diseases;

dermatological diseases;

kidney or urinary tract diseases;

liver diseases;

disease of the male or female reproductive organs such as the breast or the prostate gland;

cancer or cancer cachexia;

diseases of the head and neck, including disease of the mouth and teeth, of the eyes or of the ears;

infection with viruses, bacteria, fungi, protozoa or other organisms.

They may also be taken as a general nutritional supplement.

- 6 -

The present invention further provides a method of treatment or prevention of any of the aforesaid diseases or conditions, in particular neurological and psychiatric disorders, especially schizophrenia, depression, bipolar disorder and degenerative disorders of the brain including Alzheimer's disease and other dementias and Parkinson's disease. The treatment or preventative method is, for example, by the combined application of EPA and AA at the dosage regime of between 100mg and 10,000mg/day EPA and a ratio of EPA to AA of between 1:1 and 20:1. A precursor to AA, selected from DGLA and GLA, may be used instead of AA. The preferred range of EPA to AA (or its precursor) is between 1:1 and 5:1.

The present invention still further provides a method of treatment or prevention of any disease selected from:

15 asthma and other respiratory diseases;
 diseases of the gastrointestinal tract
 including inflammatory bowel diseases and irritable
 bowel syndrome;
20 inflammatory disease affecting any system;
 cardiovascular disease;
 any form of dyslipidaemia, any form of diabetes
 or any form of metabolic diseases;
 any form of dermatological diseases;
25 any form of kidney or urinary tract disease;
 any form of liver disease;
 any form of disease of the male or female
 reproductive system or related secondary sexual
 organs such as the breast or prostate gland;
30 any form of cancer or for cancer cachexia;
 any disease of the head and neck including
 diseases of the mouth and teeth, of the eyes or of
 the ears; and
 any form of infection with viruses, bacteria,
35 fungi, protozoa or other organisms

- 7 -

by, for example, the combined application of EPA and AA at the dosage regime of between 100mg and 10,000mg/day EPA and a ratio of EPA to AA of between 1:1 and 20:1. A precursor to AA, DGLA or GLA, may be used instead of AA.

5 The preferred range of EPA to AA (or its precursor) is between 1:1 and 5:1.

Use of the formulations of the invention in the manufacture of a medicament for the treatment or prevention of any disease or disorder, including those 10 mentioned above, is included in the present invention.

The specific therapeutic compositions proposed are ones which provide not less than 100mg and not more than 10,000mg of EPA/day combined with AA, DGLA or GLA, in doses of between 100mg and 10,000mg/day. An alternative 15 upper limit is 5,000 mg/day of the fatty acids.

Particularly preferred amounts are 1-4g per day EPA combined with 0.1 - 2.0 g per day arachidonic acid, or one of its precursors, GLA or DGLA. A still preferred composition comprises 1.5 - 3g EPA and 0.2 - 1g AA. The 20 present invention further provides a formulation, for example, in a one-a-day dose comprising 1.5 - 3 g EPA and 0.1 - 2.0 g arachidonic acid or one of its precursors.

The ratio of EPA to the omega-6 fatty acid is important because too much EPA is likely to lead to the loss of AA from membranes, while too much AA may lead to adverse 25 effects because of excessive conversion of AA to eicosanoid. The ratio of EPA to AA or DGLA or GLA should therefore never be less than 1:1, should preferably be in the range between 20:1 and 1:1, and should still 30 preferably be in the range of between 5:1 and 1:1. These combinations will ensure that the beneficial effects of EPA are enhanced and maintained even at relatively high EPA doses, because the provision of AA and its precursors

- 8 -

will prevent AA depletion which may occur when too much EPA is given alone.

During absorption from the gut and within the body, EPA moieties are readily transformed intact from one chemical
5 form to another. Simple esters such as ethyl or methyl esters are readily split by esterases and the freed fatty acids can then be bound by albumin or other binding or transport proteins or incorporated into complex lipids such as phospholipids, cholesterol ester or glycerides.
10 The fatty acids in the present formulations can therefore be administered in any form such as glycerides, esters, free acids, salts, phospholipids, amides or any other form which leads to their incorporation into the blood and cell membranes.

15 The EPA, AA, DGLA or GLA may be derived from any appropriate source including plant seed oils, microbial oils from algae or fungal or marine oils from fish or other marine animals. They may be used in the form of the natural oil, if that oil meets the required purity
20 requirements of the starting material, or may be purified to give products containing 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the fatty acid. A particularly useful form of EPA is the highly purified ethyl ester described in patent filings based on the preliminary UK filing
25 9901809.5. Synthetic routes to the fatty acids are also possible although at present are not economically feasible.

Once the oils containing the individual fatty acids have been obtained, and purified as necessary, the starting
30 materials may be blended to give the desirable ratios of EPA to AA, DGLA or GLA described above.

- 9 -

The blended fatty acid compositions may then be incorporated into any appropriate dosage form for oral, enteral, parenteral, rectal, vaginal, dermal or other route of administration. Soft or hard gelatin capsules, 5 flavoured oil blends, emulsifiers or other liquid forms, and microencapsulate powders or other dry form vehicles are all appropriate ways of administering the products.

- 10 -

Example Formulations

- (a) Soft or hard gelatin capsules each containing 500mg or 1000mg of a mix of 10 parts 95% pure ethyl-EPA to 2 parts of 95% pure AA;
- 5 (b) As in (a) but where the AA and EPA ethyl esters are replaced with the fatty acids in any other appropriate bioassimilable form such as the free acid, tri-, di- or monoglyceride, other esters, salts such as the sodium, potassium or lithium salts, amides, phospholipids or any other appropriate derivatives;
- 10 (c) As in (a) or (b) but where the EPA or EPA derivative is 50%, 60%, 70%, 80% or 90% pure and where the AA or AA derivative is 30%, 40%, 50%, 60%, 70%, 80% or 90% pure;
- 15 (d) As in (a)-(c) but where the ratio of EPA to AA is anywhere in the range from 1:1 to 20:1;
- 20 (e) As in (a)-(d) but where the material is in the form of a microencapsulated powder which can be used as a powder or compressed into tablets. Such powders may be prepared by a variety of technologies known to those skilled in the art;
- 25 (f) As in (a)-(d) but where the formulation is a liquid or emulsion, appropriately flavoured for palatable oral administration;
- (g) As in (a)-(d) but where the material is formulated in to material appropriate for topical application such as a cream or ointment;

- 11 -

- (h) As in (a)-(g) but where the AA is replaced by one of its precursors, GLA or DGLA.

Brief description of the figures

Fig 1. the metabolic pathways of the two series of
5 essential fatty acids.

Experimental Data

A trial was conducted of the administration of a placebo and three different doses of EPA, 1g, 2g and 4g/day in the treatment of schizophrenia in patients who were also taking the antischizophrenic drug clozapine. Previous pilot studies had suggested that EPA would have desirable effects and the expectation was that the higher the dose of EPA, the better would be the effect. 31 patients were entered into the study and followed for 12 weeks. They were assessed at baseline and 12 weeks using the Positive and Negative Symptom Scale for Schizophrenia (PANSS). The percentage improvements from baseline are shown in table 1. Placebo produced a small effect, 1g/day produced a larger effect, 2g/day produced a large effect of 26.0% compared to the usual 15-20% improvements on this scale generated by existing drugs for schizophrenia. It was expected that 4g/day would produce the best effect but this did not happen. The effect of 4g/day while there, was substantially less than the effect of 2g/day, and comparable to that of 1g/day.

- 12 -

Table 1. Percentage improvements from baseline to 12 weeks on the Positive and Negative Symptom Scale for Schizophrenia (PANSS) in patients given placebo, 1g/day, 2g/day or 4g/day ethyl eicosapentaenoate

	<u>Placebo</u>	<u>1g</u>	<u>2g</u>	<u>4g</u>
n	7	9	9	6
Improvement	6.0%	18.3%	26.0%	16.3%

In these patients, and also in a further series of patients, the levels of DGLA, AA, EPA and DHA were measured in human red cells before starting treatment and after 12 weeks. The results were partly expected and partly surprising and are shown in table 2. As expected there was a dose-related rise in EPA which was greater the greater the dose. It was also expected that there would be a progressive decline in AA, the larger the EPA dose, the greater the fall in AA. However, this did not happen. 1g/day of EPA produced a small rise in AA while 2g/day produced a large rise. 4g/day EPA produced the expected fall in AA.

Table 2. Changes from baseline to 12 weeks in red cell concentrations (in $\mu\text{g/g}$) of eicosapentaenoic acid (EPA) and arachidonic acid (AA) in red blood cells in four groups of schizophrenic patients given placebo or 1g/d, 2g/d or 4g/d ethyl-EPA. + means a rise and - means a fall

	<u>Placebo</u>	<u>1g</u>	<u>2g</u>	<u>4g</u>
EPA	-0.6	+2.4	+33.7	+49.0
AA	-12.6	+2.7	+29.4	-26.5

It appeared that the improvement in schizophrenic symptoms was more related to the changes in AA than to the changes in EPA. This was tested in a larger series of patients where the improvement in PANSS was correlated with the

- 13 -

changes in all the major EFAs. The values for r, the correlation coefficient, are shown in table 3 as is the statistical significance of the relationship. An r value of 1.0 means that the two parameters are perfectly related
5 while one of 0.0 means that there is no relationship whatsoever.

Table 3. Correlations between the change from baseline to 12 weeks on the total PANSS score and the change from baseline to 12 weeks in the red cell concentration of various essential fatty acids. r, the correlation coefficient from a linear regression analysis, is shown.
10 p is the statistical significance of the relationship.

	<u>Fatty acid</u>	<u>Correlation coefficient r</u>	<u>Significance p =</u>
	Dihomogammalinolenic (DGLA)	-0.51	0.09
15	Arachidonic (AA)	-0.81	0.001
	Eicosapentaenoic (EPA)	-0.07	0.84
	Docosapentaenoic (DPA)	-0.12	0.76
20	Docosahexaenoic (DHA)	-0.35	0.13

From the table it is clear that by far the strongest relationship is with AA, and the second strongest relationship is with DGLA. Rises in these two fatty acids are strongly associated with improvement in schizophrenic symptoms, as indicated by a fall in the PANSS score, hence the negative correlations. In contrast there is almost no relationship with EPA because high doses of EPA are associated with falls in red cell AA levels and the loss
25 of clinical effect.
30

These results were completely unexpected. Far from EPA itself being the most desirable fatty acid in cell membranes it seems that AA and DGLA are more helpful. The likeliest interpretation of this is that AA is desirable

- 14 -

when it is retained in membrane phospholipids and not converted to potentially dangerous eicosanoids. The effect of EPA may be to inhibit phospholipases and so keep AA in the phospholipid form. Very high doses of EPA, 5 however, displace AA and the therapeutic effect is lost.

This interpretation was supported by a pilot study in which AA itself was given to five patients with schizophrenia. The expectation was that they would improve, but in fact their condition deteriorated. The 10 administration of AA, without EPA to inhibit phospholipases, may lead to increased formation of eicosanoids rather than to incorporation of AA into phospholipids.

The conclusion to be drawn from these studies is that EPA 15 is desirable, not in itself but because it raises the AA level in membrane phospholipids. High doses of EPA, far from being valuable in themselves, may be undesirable because they lead to excessive loss of AA from membranes. The way to get around this issue, and to boost the clearly 20 desirable effects of EPA, is to keep to relatively low doses of EPA, but also to boost the level of AA by administering the EPA with either AA or one of its precursors, DGLA or gamma-linolenic acid GLA. When AA in a dose of 1g/day was given to two patients who had already 25 been taking 2g/day EPA for 3 months, they experienced a substantial further improvement without any of the worsening seen when AA was given alone.

US Patent 4,977,187 provided for combinations of n-3 fatty acids and n-6 fatty acids and vitamin E in the treatment 30 of schizophrenia. However, that patent did not direct attention to AA specifically or to EPA specifically, or to the specific combination of EPA with AA or its immediate precursors or to the specific doses and ratios of EPA and

- 15 -

AA described in this specification. Any n-6 fatty acid could be combined with any n-3 fatty acid in any ratio in US 4,977,198 and corresponding patents.

A review of the literature suggests that the phenomenon
5 described here is not only true of schizophrenia but of several disorders where EPA is therapeutically useful. There are many studies describing the value of low doses of EPA containing products in cardiovascular diseases, in inflammatory disease and in other disorders. However,
10 when investigators have gone to higher doses, these desirable therapeutic effects have been lost. To take two examples, high doses of EPA completely failed to exert beneficial effects in patients undergoing angioplasty for coronary vascular disease, or in patients with
15 inflammatory bowel disease, even though earlier studies with smaller EPA doses had given strong evidence of benefit. The authors had no real explanation for the trial failure and did not consider the possibility that excess depletion of AA may have been the cause.
20 The use of the formulations of the present invention could be very wide-ranging.

- 16 -

Claims

1. Pharmaceutical formulations, prepared by combining:
eicosapentaenoic acid or any appropriate derivative (EPA), in any biologically assimilable form in which the EPA is at least 50% pure; and
5 arachidonic acid (AA) in any biologically assimilable form.
2. Pharmaceutical formulations according to claim 1, in which the EPA is at least 90% pure.
- 10 3. Pharmaceutical formulations according to claim 1 or 2, in which the AA is at least 30% pure.
4. Pharmaceutical formulations according to claim 3, in which the AA is at least 90% pure.
5. Pharmaceutical formulations according to any preceding claim in which the ratio of EPA to AA is
15 between 1:1 and 20:1.
6. Pharmaceutical formulations according to any preceding claim in which the EPA is provided in a dose of between 100 mg and 10,000mg/day.
- 20 7. Pharmaceutical formulations according to any preceding claim containing 1 - 4 g EPA and 0.1 - 2.0 g arachidonic acid (AA).
8. Pharmaceutical formulations containing
25 1.5 - 3 g eicosapentaenoic acid or any appropriate derivative (EPA), in any biologically assimilable form; and 0.1 - 2.0 g arachidonic acid (AA) in any biologically assimilable form.

- 17 -

9. Pharmaceutical formulations according to any preceding claim in which the active ingredient consists essentially wholly of the EPA and AA.
10. Formulations according to any preceding claim in which the AA is replaced by its precursor DGLA.
5
11. Formulations according to any preceding claim in which the AA is replaced by its precursor GLA.
12. Pharmaceutical formulations comprising EPA and an AA precursor, selected from DGLA and GLA, in which the EPA is provided in a dose of between 100mg and
10 10,000mg/day and in which the ratio of EPA to AA precursor is between 1:1 and 20:1.
13. Formulations according to any preceding claim further comprising a flavourant or emulsifier.
15
14. Formulations according to any preceding claim in which the EPA is composed of a triglyceride or ethyl ester which is 50% pure or purer, preferably more than 90% pure.
20
15. Formulations according to any preceding claim for the treatment of any psychiatric, neurological or other central or peripheral nervous system disease, in particular schizophrenia, depression, bipolar disorder and degenerative disorders of the brain including Alzheimer's disease and other dementias and Parkinson's disease.
25
16. Formulations according any of claims 1-14 for use in the treatment of any disease selected from:
asthma and other respiratory diseases;

- 18 -

diseases of the gastrointestinal tract
including inflammatory bowel diseases and irritable
bowel syndrome;

- 5 inflammatory disease affecting any system;
cardiovascular disease;
any form of dyslipidaemia, any form of diabetes
or any form of metabolic diseases;
any form of dermatological diseases;
any form of kidney or urinary tract disease;
10 any form of liver disease;
any form of disease of the male or female
reproductive system or related secondary sexual
organs such as the breast or prostate gland;
any form of cancer or for cancer cachexia;
15 any disease of the head and neck including
diseases of the mouth and teeth, of the eyes or of
the ears; and
any form of infection with viruses, bacteria,
fungi, protozoa or other organisms.
- 20 17. A method of treatment or prevention of any
psychiatric, neurological or other central or
peripheral nervous system disease, in particular
schizophrenia, depression, bipolar disorder and
degenerative disorders of the brain including
25 Alzheimer's disease and other dementias and
Parkinson's disease, by the application of a
formulation according to any of claims 1-14.
18. A method of treatment or prevention of any disease
selected from:
30 asthma and other respiratory diseases;

- 19 -

diseases of the gastrointestinal tract
including inflammatory bowel diseases and irritable
bowel syndrome;

5 inflammatory disease affecting any system;
 cardiovascular disease;

any form of dyslipidaemia, any form of diabetes
or any form of metabolic diseases;


10 any form of dermatological diseases;
 any form of kidney or urinary tract disease;
 any form of liver disease;

15 any form of disease of the male or female
 reproductive system or related secondary sexual
 organs such as the breast or prostate gland;
 any form of cancer or for cancer cachexia;

20 any disease of the head and neck including
 diseases of the mouth and teeth, of the eyes or of
 the ears; and
 any form of infection with viruses, bacteria,
 fungi, protozoa or other organisms
 by the application of a formulation according to any
 of claims 1-14.

Fig. 1

ESSENTIAL FATTY ACID (EFA) METABOLISM



INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/GB 01/02717

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/202 A61P25/18 // (A61K31/202, A61K31:202)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, CHEM ABS Data, MEDLINE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 516 800 A (HORROBIN DAVID F) 14 May 1996 (1996-05-14) column 3, line 10 - line 21; example 3	1-18
X	US 4 977 187 A (HORROBIN DAVID F) 11 December 1990 (1990-12-11) examples 2,5,7	1-18
X	US 5 198 468 A (HORROBIN DAVID F) 30 March 1993 (1993-03-30) column 3, line 16 - line 25; examples 2,3	1-18
X	EP 0 711 503 A (SCOTIA HOLDINGS PLC) 15 May 1996 (1996-05-15) page 3, line 31 - line 39; example 3	1-18
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

• Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

29 October 2001

Date of mailing of the international search report

19/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Pilling, S

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/GB 01/02717

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 713 653 A (SCOTIA HOLDINGS PLC) 29 May 1996 (1996-05-29) page 3, line 26 - line 34; example 3	1-18
X	US 4 526 902 A (RUBIN DAVID) 2 July 1985 (1985-07-02) column 2, line 43 - line 60	1-18
X	US 5 516 801 A (HORROBIN DAVID F ET AL) 14 May 1996 (1996-05-14) column 3, line 26 - line 35; example 4	1-18
X	US 5 583 159 A (HORROBIN DAVID F ET AL) 10 December 1996 (1996-12-10) abstract; examples 11-20	1-16,18
X	US 5 378 732 A (HORROBIN DAVID F ET AL) 3 January 1995 (1995-01-03) example abstract	1-16,18
X	US 5 252 333 A (HORROBIN DAVID F) 12 October 1993 (1993-10-12) column 4, line 21 - line 38; examples 2,4,5,7,9,10,12-14,27,28	1-18
X	WO 99 33355 A (SAWATZKI GUENTHER ;FARWER SANDRA (DE); KLIEM MICHAEL (DE); BOEHM G) 8 July 1999 (1999-07-08) abstract; table 2	1-16,18
X	US 5 260 067 A (ZHENG XU) 9 November 1993 (1993-11-09) column 15, line 56 - line 67; examples 1,6,7	1-16,18
X	DATABASE WPI Section Ch, Week 199932 Derwent Publications Ltd., London, GB; Class B05, AN 1999-371708 XP002181361 & CN 1 212 867 A (SONG F), 7 April 1999 (1999-04-07) abstract	1-16,18
X	DATABASE WPI Section Ch, Week 199443 Derwent Publications Ltd., London, GB; Class B05, AN 1994-347054 XP002181362 & JP 06 271464 A (TOKIWA YAKUHIN KOGYO KK) , 27 September 1994 (1994-09-27) abstract	1-16,18
		-/-

INTERNATIONAL SEARCH REPORT

Internal Application No	PCT/GB 01/02717
-------------------------	-----------------

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 199330 Derwent Publications Ltd., London, GB; Class B05, AN 1993-239917 XP002181364 & JP 05 163142 A (TOKIWA YAKUHIN KOGYO KK) , 29 June 1993 (1993-06-29) abstract —	1-16,18
X	DATABASE WPI Section Ch, Week 199231 Derwent Publications Ltd., London, GB; Class B05, AN 1992-253493 XP002181363 & JP 04 169524 A (NISSEI MARINE KOGYO KK), 17 June 1992 (1992-06-17) abstract —	1-16,18
X	PATENT ABSTRACTS OF JAPAN vol. 009, no. 287 (C-314), 14 November 1985 (1985-11-14) & JP 60 132916 A (NISSHIN SEIYU KK), 16 July 1985 (1985-07-16) abstract —	1-16,18

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-16 part

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were, in fact, retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims was impossible. Consequently, the search was restricted towards (i) the methods defined in Claim 17 and 18 and (ii) the pharmaceutical formulations defined in Claims 1 to 16 IN SO FAR as these pharmaceutical formulations have previously been used in a method as defined in Claim 17 and 18. The Applicant is warned however, that further searching may be necessary, if and when the scope of the claims is restricted.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Internat.	Application No
PCT/GB 01/02717	

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5516800	A	14-05-1996		AT 144706 T AU 666782 B2 AU 5183093 A AU 5232996 A CA 2109777 A1 CN 1104494 A DE 69305723 D1 DE 69305723 T2 DK 599576 T3 EP 0599576 A1 EP 0733360 A2 ES 2093935 T3 GR 3021692 T3 HK 114297 A JP 6199663 A NO 934266 A NZ 250265 A RU 2123844 C1 SG 47838 A1 ZA 9308835 A		15-11-1996 22-02-1996 09-06-1994 18-07-1996 27-05-1994 05-07-1995 05-12-1996 03-04-1997 25-11-1996 01-06-1994 25-09-1996 01-01-1997 28-02-1997 29-08-1997 19-07-1994 27-05-1994 24-06-1997 27-12-1998 17-04-1998 02-08-1994
US 4977187	A	11-12-1990		AT 87825 T AU 618814 B2 AU 3597489 A AU 633442 B2 AU 7943491 A CA 1334004 A1 DE 68905863 D1 DE 68905863 T2 EP 0347056 A1 EP 0454102 A2 ES 2053990 T3 IE 63303 B JP 2032017 A JP 2796838 B2 KR 129666 B1 NZ 229423 A NZ 239126 A US 5120760 A ZA 8904380 A		15-04-1993 09-01-1992 14-12-1989 28-01-1993 12-09-1991 17-01-1995 13-05-1993 26-08-1993 20-12-1989 30-10-1991 01-08-1994 05-04-1995 01-02-1990 10-09-1998 09-04-1998 28-10-1992 27-07-1997 09-06-1992 28-02-1990
US 5198468	A	30-03-1993		AT 81453 T AU 608012 B2 AU 1821888 A CA 1310911 A1 DE 3875286 D1 DE 3875286 T2 EP 0296751 A1 ES 2045120 T3 GR 3006403 T3 HK 158496 A IE 63386 B JP 1022819 A JP 2070571 C JP 7088301 B KR 9610832 B1 ZA 8804484 A		15-10-1992 21-03-1991 05-01-1989 01-12-1992 19-11-1992 11-03-1993 28-12-1988 16-01-1994 21-06-1993 30-08-1996 19-04-1995 25-01-1989 10-07-1996 27-09-1995 09-08-1996 29-03-1989

INTERNATIONAL SEARCH REPORT

Internal Application No	PCT/GB 01/02717
-------------------------	-----------------

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0711503	A	15-05-1996		AU 3782895 A CA 2162739 A1 CN 1135841 A EP 0711503 A2 FI 955449 A JP 8205769 A NO 954573 A NZ 280457 A SG 33588 A1 ZA 9509683 A	23-05-1996 15-05-1996 20-11-1996 15-05-1996 15-05-1996 13-08-1996 15-05-1996 24-11-1997 18-10-1996 29-05-1996
EP 0713653	A	29-05-1996		AU 3786995 A CA 2163466 A1 CN 1132607 A EP 0713653 A1 FI 955618 A JP 8205832 A NO 954726 A NZ 280468 A SG 35039 A1 ZA 9509843 A	30-05-1996 24-05-1996 09-10-1996 29-05-1996 24-05-1996 13-08-1996 24-05-1996 26-08-1998 01-02-1997 29-05-1996
US 4526902	A	02-07-1985		CA 1239587 A1 CH 661209 A5 DE 3438630 A1 FR 2553662 A1 GB 2148713 A ,B IT 1178170 B JP 60115522 A SE 462701 B SE 8405308 A	26-07-1988 15-07-1987 02-05-1985 26-04-1985 05-06-1985 09-09-1987 22-06-1985 20-08-1990 25-04-1985
US 5516801	A	14-05-1996		AT 159856 T AU 666747 B2 AU 4466693 A CA 2104567 A1 CN 1091285 A ,B DE 69315020 D1 DE 69315020 T2 DK 585026 T3 EP 0585026 A1 ES 2110060 T3 GR 3025898 T3 HK 1000997 A1 JP 6157303 A NO 932983 A NZ 248422 A RU 2122409 C1 US 5618558 A ZA 9305976 A AT 164518 T AU 666748 B2 AU 4474893 A CA 2104566 A1 CN 1090490 A DE 69317716 D1 DE 69317716 T2 DK 585027 T3	15-11-1997 22-02-1996 24-02-1994 22-02-1994 31-08-1994 11-12-1997 16-04-1998 02-06-1998 02-03-1994 01-02-1998 30-04-1998 15-05-1998 03-06-1994 22-02-1994 24-06-1997 27-11-1998 08-04-1997 14-03-1994 15-04-1998 22-02-1996 24-02-1994 22-02-1994 10-08-1994 07-05-1998 17-09-1998 11-05-1998

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/GB 01/02717

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 5516801	A		EP 0585027 A1 ES 2117104 T3 GR 3026708 T3 JP 6172169 A NO 932984 A NZ 248451 A RU 2122408 C1 US 5888541 A ZA 9306133 A	02-03-1994 01-08-1998 31-07-1998 21-06-1994 22-02-1994 27-07-1997 27-11-1998 30-03-1999 17-03-1994
US 5583159	A	10-12-1996	US 5663202 A AU 673868 B2 AU 5395894 A CA 2114047 A1 CN 1104496 A EP 0609064 A1 JP 6279277 A NO 940266 A NZ 250757 A ZA 9400392 A	02-09-1997 28-11-1996 04-08-1994 27-07-1994 05-07-1995 03-08-1994 04-10-1994 27-07-1994 24-06-1997 01-09-1994
US 5378732	A	03-01-1995	AT 133334 T AU 680725 B2 AU 1656395 A AU 657009 B2 AU 2968792 A CA 2084273 A1 DE 69207885 D1 DE 69207885 T2 DK 551729 T3 EP 0551729 A1 EP 0676197 A2 ES 2082390 T3 GR 3019270 T3 HK 131096 A JP 5286854 A NO 303047 B1 NZ 245343 A US 5859055 A ZA 9209316 A	15-02-1996 07-08-1997 29-06-1995 23-02-1995 03-06-1993 03-06-1993 07-03-1996 25-07-1996 12-02-1996 21-07-1993 11-10-1995 16-03-1996 30-06-1996 26-07-1996 02-11-1993 25-05-1998 24-06-1997 12-01-1999 09-09-1993
US 5252333	A	12-10-1993	US 5422115 A AT 65182 T AU 618730 B2 AU 1536188 A CA 1306944 A1 DE 3863678 D1 DK 225588 A EP 0289204 A2 ES 2040847 T3 GR 3002426 T3 HK 127793 A IE 60568 B JP 1013021 A JP 2699083 B2 KR 9613433 B1 NZ 224380 A SG 113593 G	06-06-1995 15-08-1991 09-01-1992 27-10-1988 01-09-1992 22-08-1991 28-10-1988 02-11-1988 16-07-1996 30-12-1992 26-11-1993 27-07-1994 17-01-1989 19-01-1998 05-10-1996 25-06-1991 21-01-1994

INTERNATIONAL SEARCH REPORT

Internal application No

PCT/GB 01/02717

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 5252333	A		ZA 8802947 A AT 96327 T AU 2147988 A CA 1332358 A1 DE 3885212 D1 DE 3885212 T2 DK 469488 A EP 0305097 A2 EP 0432700 A2 IE 61750 B JP 1083021 A KR 9700043 B1 NZ 225909 A ZA 8806322 A	22-02-1989 15-11-1993 02-03-1989 11-10-1994 02-12-1993 07-04-1994 26-02-1989 01-03-1989 19-06-1991 30-11-1994 28-03-1989 04-01-1997 28-04-1992 30-05-1989
WO 9933355	A 08-07-1999		DE 19757414 A1 AU 2416299 A BR 9814467 A CN 1282223 T WO 9933355 A2 EP 1041896 A2 NO 20003265 A	01-07-1999 19-07-1999 10-10-2000 31-01-2001 08-07-1999 11-10-2000 22-06-2000
US 5260067	A 09-11-1993		CN 1042658 A DE 68927163 D1 DE 68927163 T2 EP 0381823 A2 JP 2262514 A	06-06-1990 17-10-1996 03-04-1997 16-08-1990 25-10-1990
CN 1212867	A 07-04-1999		NONE	
JP 6271464	A 27-09-1994		NONE	
JP 5163142	A 29-06-1993		NONE	
JP 4169524	A 17-06-1992		NONE	
JP 60132916	A 16-07-1985		NONE	